Ixekizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Indications

Ixekizumab is FDA-indicated for the adult treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.

Ixekizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Ixekizumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+17819995354	marketing@targetmol.com	United States	32281	58
Aladdin Scientific		tp@aladdinsci.com	United States	57505	58
Shanghai EFE Biological Technology Co., Ltd.	021-65675885 18964387627	info@efebio.com	China	9803	58
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	7988	62
BOC Sciences	--	info@bocsci.com	USA	0	65
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
Hubei Kele Fine Chemical Co., Ltd	027-59101668 19945030958	2881924765@qq.com	China	7997	58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.	+86-027-59232304 15387063101	2881924050@qq.com	China	10026	58

---

• Ixekizumab
• Research Grade Ixekizumab(DHH28801)
• Ixekizumab (anti-CTLA-8)
• LY2439821
• Research Grade Ixekizumab
• 1143503-69-8